Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $8.00 Price Target at UBS Group

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective boosted by UBS Group from $7.00 to $8.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on CATX. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday. Royal Bank Of Canada lowered their target price on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday. BTIG Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday. Piper Sandler initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target on the stock. Finally, Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Performance

CATX opened at $4.86 on Wednesday. The company has a current ratio of 5.17, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a one year low of $1.60 and a one year high of $6.16. The business’s 50-day simple moving average is $4.30 and its 200-day simple moving average is $3.43.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. As a group, analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Perspective Therapeutics in the fourth quarter valued at approximately $84,000. XTX Topco Ltd grew its holdings in Perspective Therapeutics by 36.5% during the 4th quarter. XTX Topco Ltd now owns 82,476 shares of the company’s stock valued at $227,000 after buying an additional 22,074 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at $31,000. Opaleye Management Inc. acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $3,257,000. Finally, Engineers Gate Manager LP acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: B. Riley raised its price target from $11 to $13 and maintained a “Buy” rating — a sizeable upside projection that signals stronger sell‑side conviction in the company’s growth/clinical roadmap. B. Riley Price Target Raise
• Positive Sentiment: UBS raised its price target from $7 to $8 and kept a “Buy” rating, providing additional analyst support for upside potential. UBS Price Target Raise
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating with an $11 target — another vote of confidence from a major biotech analyst. Wedbush Rating Reaffirmation
• Positive Sentiment: Perspective announced that updated data for its lead radiopharmaceutical, [212Pb]VMT-α-NET, was accepted for poster presentation at AACR 2026 — this raises scientific visibility and could help commercial/regulatory momentum if the data remain favorable. The company previously reported encouraging anti‑tumor activity (76% without progression in a subset) and no dose‑limiting toxicities in interim analyses. AACR Presentation Acceptance
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — an event that can be a catalyst for volatility as investors reassess cash runway, R&D spend and trial progress. Earnings Release Date
• Neutral Sentiment: Perspective published full‑year 2025 results and business highlights; these filings provide more detail on cash, operating burn and program timelines that investors will parse for runway and dilution risk. Full‑Year 2025 Results
• Negative Sentiment: Royal Bank of Canada trimmed its target from $18 to $14 (still “Outperform”) — a downward revision that could moderate upside expectations and trigger short‑term profit‑taking. RBC Target Lowered
• Negative Sentiment: Clinical safety data include Grade 3+ treatment‑emergent adverse events in ~37.5% of patients (one transient Grade 4 reported); these safety signals may temper enthusiasm until larger cohorts and confirmatory data are available. Clinical Safety Details

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.